Physician profile
Ani Balmanoukian
NPI 1063558682
$842,257.79
in general payments reported to CMS, 2019-2025
29 companies · $169K in 2025
The $169K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $94K · 2021: $69K · 2022: $137K · 2023: $170K · 2024: $112K · 2025: $169K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $368K · Consulting Fee: $43K · Travel and Lodging: $32K · Food and Beverage: $7,042 · Honoraria: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $368,311.83 |
| Consulting Fee | $42,500.00 |
| Travel and Lodging | $31,858.90 |
| Food and Beverage | $7,042.12 |
| Honoraria | $1,913.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $327,654.96 | 2019-2025 | Tagrisso, Imfinzi, Datroway |
| E.R. Squibb & Sons, L.L.C. | $284,001.95 | 2019-2025 | Opdivo, Krazati, Augtyro |
| Genentech USA, INC. | $54,337.67 | 2019-2023 | Tecentriq |
| Mirati Therapeutics, INC. | $40,274.70 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $30,152.86 | 2022-2025 | Libtayo |
| Pfizer INC. | $29,815.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $21,106.87 | 2019-2025 | Keytruda |
| Daiichi Sankyo INC. | $15,376.47 | 2023-2025 | Datroway, Enhertu |
| Amgen INC. | $8,089.29 | 2019-2025 | Imdelltra (Amg757) |
| Regeneron Pharmaceuticals, INC. | $5,001.50 | 2021-2022 | |
| Abbvie INC. | $4,827.75 | 2024-2025 | |
| Genzyme Corporation | $4,117.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,811.75 | 2019-2020 | |
| F. Hoffmann-La Roche Ag | $2,965.22 | 2019 | |
| Janssen Scientific Affairs, LLC | $2,497.50 | 2025 | Rybrevant |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $1,514.27 | 2023-2024 | Braftovi, Lorbrena, Mektovi |
| Catalyst Pharmaceuticals, INC. | $1,500.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,321.48 | 2021-2023 | |
| Beigene, Ltd. | $1,173.33 | 2021 | |
| Incyte Corporation | $1,087.70 | 2019 | |
| Blueprint Medicines Corporation | $1,073.25 | 2020-2023 | |
| Lilly USA, LLC | $362.08 | 2019-2021 | |
| Sirtex Medical INC | $130.16 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.79 | 2023 | |
| Sobi, INC | $22.46 | 2025 | |
| Janssen Biotech, INC. | $15.38 | 2025 | Rybrevant |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ani Balmanoukian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.